Caspofungin
The first echinocandin, a cyclic lipopeptide that attacks the fungal cell wall
Caspofungin is a semi-synthetic cyclic lipopeptide that blocks the enzyme fungi use to build their cell walls, a target human cells lack. Approved as Cancidas in 2001, it is given by daily intravenous infusion for serious Candida infections and some cases of invasive aspergillosis.
Manufacturer's recommended dosing (FDA label): 70 mg loading dose, then 50 mg, Once daily, Intravenous, over about 1 hour Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
What is it?
Echinocandins are cyclic lipopeptides, rings of six amino acids carrying a fatty tail, made by modifying natural products of fungi. They block beta-(1,3)-D-glucan synthase, which builds a polysaccharide in the fungal cell wall. Because human cells have no cell wall, the drug targets the fungus selectively. Caspofungin, approved as Cancidas in 2001, was the first of the class.
In a 2002 trial in 224 patients with invasive candidiasis, caspofungin was as effective as amphotericin B (73.4% against 61.7% success) with fewer side effects. In 1,095 patients with persistent fever and neutropenia, it was noninferior to liposomal amphotericin B as empirical therapy, with better outcomes in those with baseline fungal infections. It was also studied as salvage for invasive aspergillosis in patients who had failed or not tolerated other drugs. Its other early trials were in mucosal disease: in Candida oesophagitis, mostly in advanced HIV, it matched intravenous fluconazole (81% against 85% favourable response), though symptoms came back somewhat more often after it (28% against 17% at four weeks, not significant).
Children were the next question. In childhood acute myeloid leukaemia, caspofungin prophylaxis halved invasive fungal disease against fluconazole (3.1% against 7.2%) and cut aspergillosis, and in adults starting induction for AML or myelodysplasia it protected about as well as intravenous itraconazole (52% against 51% finished prophylaxis free of fungal infection); after stem cell transplant in children, infections were too rare on either caspofungin or triazoles to separate them. In neonates, a trial against amphotericin B deoxycholate stopped early with similar fungal-free survival and fewer adverse events.
It became the comparator against which newer drugs were measured. In the ACTIVE trial, isavuconazole failed to match it for invasive candidiasis (60.3% against 71.1% success at the end of intravenous therapy), and in ReSTORE and a four-trial meta-analysis, weekly rezafungin matched daily caspofungin for cure and mortality. Micafungin was measured against it too: at 100 or 150 mg a day it was non-inferior in 595 patients with candidaemia (success 76.4% and 71.4% against 72.3%). Pooled across nine randomised trials it matched other antifungals on response and mortality with fewer adverse events, and against liposomal amphotericin B in three trials (1,249 patients) it matched efficacy with far fewer clinical adverse events and discontinuations. One Chinese study added it to voriconazole for aspergillosis in COPD, an observational, off-label combination. Outside the bloodstream, as 0.5% eye drops, an experimental use, it healed fewer fungal corneal ulcers than voriconazole 1% in a 34-patient pilot trial (70.6% against 100%, not significant) and only one of four Fusarium infections against five of five, though the authors called it a viable option.
It is given by slow infusion over about an hour, never as a bolus, after a 70 mg loading dose, then 50 mg daily; children are dosed by body surface area. The dose is cut to 35 mg in moderate liver impairment and raised to 70 mg with rifampin. The label warns of hypersensitivity, liver effects, and raised liver enzymes when given with cyclosporine. Its plasma half-life has a 9-to-11-hour phase and a longer phase of 40 to 50 hours. Higher doses have been tried in healthy volunteers: single doses of 150 and 210 mg and 100 mg a day for three weeks were well tolerated apart from infusion-site reactions and one reversible ALT rise, with exposure rising in proportion to dose.
Mechanism of Action
Caspofungin, the first echinocandin, kills Candida and inhibits Aspergillus by blocking cell-wall glucan synthesis.
Glucan synthase
Inhibits 1,3-beta-D-glucan synthase, an enzyme human cells do not have.
Liver handling
Dose is reduced in moderate hepatic impairment and raised with enzyme inducers such as rifampin (label 2.4-2.5).
Once daily
A 9-to-11-hour phase and a longer 40-to-50-hour phase (label 12.3).
Published Research
The studies behind caspofungin, from their PubMed abstracts.
Against amphotericin B in invasive candidiasis
In 224 patients in the modified intention-to-treat analysis, success was 73.4% on caspofungin and 61.7% on amphotericin B, similar efficacy; among patients meeting prespecified evaluation criteria, caspofungin was superior.
Empirical therapy in fever and neutropenia
In 1,095 patients, overall success was 33.9% on caspofungin and 33.7% on liposomal amphotericin B, meeting noninferiority; with baseline fungal infections, success was 51.9% against 25.9%, and survival at seven days after therapy 92.6% against 89.2%.
Refractory invasive aspergillosis
Among 83 patients refractory to or intolerant of other therapy, 45% had a favourable response, including 50% with pulmonary aspergillosis; two stopped for drug-related adverse events, and kidney and liver toxicity were infrequent.
Prophylaxis in childhood leukaemia
In 517 children and young adults with acute myeloid leukaemia, invasive fungal disease over 5 months was 3.1% on caspofungin prophylaxis against 7.2% on fluconazole, with fewer aspergillosis cases (0.5% against 3.1%).
ReSTORE: the comparator for weekly rezafungin
In 199 patients with candidaemia or invasive candidiasis, daily caspofungin and once-weekly rezafungin gave similar global cure at day 14 (61% against 59%) and 30-day mortality (21% against 24%).
Prophylaxis in children after transplant
In 290 children and young adults after allogeneic stem cell transplant, proven or probable fungal disease by day 42 was 1.4% on caspofungin and 1.4% on fluconazole or voriconazole; the trial stopped early because infections were so rare.
Neonates: against amphotericin B
In a double-blind trial in neonates and young infants with invasive candidiasis, stopped for low enrolment after 49 treated, fungal-free survival was 71.0% on caspofungin and 68.8% on amphotericin B deoxycholate, with fewer adverse events on caspofungin.
With voriconazole in COPD aspergillosis
In COPD patients with invasive pulmonary aspergillosis, adding caspofungin to voriconazole was associated with higher overall efficacy (89.5% against 65.8%) and shorter hospital stay in one Chinese study; combination therapy is not a labelled use.
ACTIVE: isavuconazole fell short of it
In 400 patients with candidaemia or invasive candidiasis, overall response at the end of intravenous therapy was 71.1% on caspofungin and 60.3% on isavuconazole, so isavuconazole failed non-inferiority; mortality and safety were similar.
Fungal keratitis: eye drops against voriconazole
In a pilot randomised trial in 34 patients with fungal keratitis, topical caspofungin 0.5% healed 70.6% of ulcers against 100% with voriconazole 1% (P = 0.060) and only 1 of 4 Fusarium infections against 5 of 5; final visual acuity and scar size did not differ significantly, and the authors judged it a possible first-line option. Topical use is experimental.
Oesophageal candidiasis: against fluconazole
In a double-blind trial in 175 evaluable adults with Candida oesophagitis, 87% with advanced HIV, intravenous caspofungin 50 mg daily gave a favourable response in 81% against 85% on fluconazole 200 mg (difference -4%, 95% CI -15% to +8%) with no serious drug-related adverse events; symptoms recurred within four weeks in 28% against 17% (P = 0.19).
Micafungin measured against it
In a double-blind trial in 595 adults with candidaemia or invasive candidiasis, micafungin 100 or 150 mg daily was non-inferior to standard caspofungin (70 mg, then 50 mg daily), with treatment success of 76.4% and 71.4% against 72.3% and no differences in mortality, relapse or adverse events.
Higher doses in healthy volunteers
In a randomised double-blind study with a Merck first author, single 150 and 210 mg doses (16 volunteers) and 100 mg daily for 21 days (20 volunteers) were generally well tolerated apart from infusion-site reactions and one reversible ALT rise; exposure rose in proportion to dose, with a beta-phase half-life of about 8 to 13 hours.
Prophylaxis in AML: against itraconazole
In an open-label randomised trial in 192 evaluable patients starting induction for acute myeloid leukaemia or myelodysplasia, 52% on caspofungin and 51% on intravenous itraconazole completed prophylaxis without fungal infection; 7 and 5 developed documented infections, deaths from fungal infection were 4 against 2 (P = 0.57), and grade 3-4 adverse events were comparable.
Against rezafungin: four trials pooled
Across 4 randomised trials of 677 patients, global cure at day 14, culture clearance, mycological eradication, adverse events and 30-day mortality did not differ between daily caspofungin and weekly rezafungin.
The first echinocandin
A review of caspofungin as the first licensed echinocandin, its mechanism against the fungal cell wall and its early clinical development.
Nine randomised trials pooled
A meta-analysis of nine randomised trials of prophylaxis and treatment found caspofungin similar to other antifungals in favourable response (risk ratio 1.07), microbiological response, mortality (0.98) and relapse, mainly in Candida infections, with fewer clinical and laboratory adverse events (risk ratio 0.66 for each).
Against liposomal amphotericin B: three trials
A meta-analysis of three trials (1,249 patients with invasive fungal infection or febrile neutropenia) found caspofungin equal to liposomal amphotericin B in overall response (risk ratio 1.02) and mortality, with fewer clinical (0.20) and laboratory (0.69) adverse events and discontinuations (0.26).
Dosing Data
Caspofungin is a hospital infusion given over about an hour once daily after a loading dose; children are dosed by body surface area.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Caspofungin Acetate (injection): For Injection: 50 mg or 70 mg lyophilized powder (plus allowance for overfill) in a single-dose vial for reconstitution. Forms the label lists: single-dose vials.
Source: Caspofungin Acetate (injection) label, section 3 (DailyMed version 2, effective July 29, 2026).
Mixing a vial: a worked example
The approved product Caspofungin Acetate (injection) is a powder that is mixed before use, with the liquid and volume its label names. Follow the label, not a general example. Its label says: “Dilution of the Reconstituted Solution in the Intravenous Bag for Infusion Aseptically transfer the appropriate volume (mL) of reconstituted caspofungin acetate for injection to an intravenous (IV) bag (or bottle) containing 250 mL of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection or Lactated Ringers Injection.”
Source: Caspofungin Acetate (injection) label, sections 2 and 3 (DailyMed version 2, effective July 29, 2026).
Storage before and after mixing
Before mixing or first use: “Store refrigerated between 2° and 8°C (36° and 46°F).”
After mixing or first use: “The reconstituted solution of caspofungin acetate for injection in the vial may be stored for up to one hour at ≤25°C (≤77°F) prior to the preparation of the infusion solution in the intravenous bag or bottle.” “This diluted infusion solution in the intravenous bag or bottle must be used within 24 hours if stored at ≤25°C (≤77°F) or within 48 hours if stored refrigerated at 2 to 8°C (36 to 46°F).” “Discard unused portion.”
Source: Caspofungin Acetate (injection) label, sections 16 and 2 (DailyMed version 2, effective July 29, 2026).
How it is taken
As the approved label gives it: Intravenous, over about 1 hour (Once daily; Label: adults, all indications except oesophageal candidiasis); Intravenous (Once daily; Label: adults, oesophageal candidiasis).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of beta-phase half-life 9 to 11 hours, with a longer gamma phase of 40 to 50 hours. After about five half-lives almost none is left.
How long the doses were given: Label: adults, all indications except oesophageal candidiasis: Set by indication and response; Label: adults, oesophageal candidiasis: Set by response; Label: children 3 months to 17 years: Set by indication.
When effects appear: unknown; no source on this page gives a time to effect for Caspofungin. Results reported in the studies are under Published Research.
Source: half-life: Cancidas prescribing information, section 12.3 (DailyMed set 3bad23a6, effective October 11, 2024); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Fewer drug-related adverse events than amphotericin B in the candidiasis trial; Infrequent kidney and liver toxicity in the aspergillosis study. Full list and cautions ↓
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Caspofungin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
- cyclosporine: raises caspofungin exposure (AUC) with transient ALT/AST increases; monitor liver enzymes
- tacrolimus: monitor tacrolimus trough concentrations and adjust its dose
- rifampin: expected to lower caspofungin concentrations; label gives a higher daily caspofungin dose
- efavirenz, nevirapine, phenytoin, dexamethasone, carbamazepine: hepatic enzyme inducers: label says to consider a higher daily caspofungin dose
Every peptide's record, with its source: the interaction matrix.
Source: Merck. CANCIDAS (caspofungin acetate) US prescribing information, section 7. DailyMed version of October 11, 2024, read October 3, 2026.
Checking what you bought
Unknown: no published independent test of Caspofungin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Caspofungin's expected mass, 1,093.3 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Cancidas (Merck), NDA 021227, on January 26, 2001, for adults and children 3 months and older). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Cancidas label (DailyMed, effective October 11, 2024).
Legal Status
Caspofungin is an approved prescription drug in the US.
Frequently Asked Questions
?Is caspofungin a peptide?
Yes. It is a cyclic lipopeptide, a ring of six amino acids with a fatty side chain, made by chemically modifying a natural fungal product.
?What is caspofungin used for?
Serious Candida infections including candidaemia, esophageal candidiasis, suspected fungal infection in febrile neutropenic patients, and invasive aspergillosis that has not responded to other drugs.
?How is it given?
By slow intravenous infusion once a day, usually after a loading dose on the first day. It cannot be taken by mouth.
?Does liver disease change the dose?
Yes. The label cuts the adult daily dose to 35 mg in moderate hepatic impairment, after a 70 mg loading dose where appropriate, and raises it to 70 mg daily with rifampin.
?Is it better than the newer antifungals?
Not worse: isavuconazole failed to show non-inferiority against it in invasive candidiasis, and weekly rezafungin matched it, offering less frequent dosing rather than better cure rates.
References
- [fda] US FDA, Drugs@FDA (openFDA): CANCIDAS, NDA 021227 (January 26, 2001). Read October 3, 2026.
- [fda-pi] FDA. Cancidas (caspofungin acetate) US prescribing information (DailyMed set 3bad23a6-09a6-4194-9182-093ed61bc71c, version 42, effective October 11, 2024). Read October 3, 2026.
- [clinical-trial] Mora-Duarte J, et al. "Comparison of caspofungin and amphotericin B for invasive candidiasis." N Engl J Med, 2002;347(25):2020-9. PMID: 12490683.
- [clinical-trial] Walsh TJ, et al. "Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia." N Engl J Med, 2004;351(14):1391-402. PMID: 15459300.
- [clinical-trial] Maertens J, et al. "Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy." Clin Infect Dis, 2004;39(11):1563-71. PMID: 15578352.
- [pubmed] Cornely OA, et al. "The first echinocandin: caspofungin." Mycoses, 2002;45 Suppl 3:56-60. PMID: 12690973.
- [clinical-trial] Fisher BT, et al. "Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial." JAMA, 2019;322(17):1673-1681. PMID: 31688884.
- [clinical-trial] Thompson GR 3rd, et al. "Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial." Lancet, 2023;401(10370):49-59. PMID: 36442484.
- [clinical-trial] Dvorak CC, et al. "A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant." J Pediatric Infect Dis Soc, 2021;10(4):417-425. PMID: 33136159.
- [clinical-trial] Kim J, et al. "A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age." J Antimicrob Chemother, 2020;75(1):215-220. PMID: 31586424.
- [pubmed] Zhang J, et al. "Efficacy of voriconazole combined with caspofungin in treating Chronic Obstructive Pulmonary Disease patients with invasive pulmonary aspergillosis: impacts on clinical outcomes, inflammatory cytokines, and immune markers." Front Immunol, 2026;17:1831585. PMID: 42553150.
- [fda-pi] Caspofungin acetate for injection US prescribing information (Sagent; DailyMed set 08fb61ee, version 2, effective July 29, 2026), sections 2.1-2.5; read through openFDA October 6, 2026.
- [pubmed] Kullberg BJ, et al. "Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial." Clin Infect Dis, 2019;68(12):1981-1989. PMID: 30289478.
- [pubmed] Al Diab Al Azzawi M, et al. "Rezafungin vs caspofungin for the treatment of invasive candidiasis: A systematic review and meta-analysis." Diagn Microbiol Infect Dis, 2025;113(3):116994. PMID: 40651396.
- [pubmed] Atighehchian M, et al. "Comparative efficacy and safety of topical caspofungin 0.5% and voriconazole 1% for fungal keratitis: a pilot clinical trial." Sci Rep, 2025;15(1):38879. PMID: 41198723.
- [pubmed] Villanueva A, et al. "A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis." Am J Med, 2002;113(4):294-9. PMID: 12361815.
- [pubmed] Pappas PG, et al. "Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis." Clin Infect Dis, 2007;45(7):883-93. PMID: 17806055.
- [pubmed] Yuan X, et al. "Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: a meta-analysis of randomized controlled trials." Pharmazie, 2012;67(4):267-73. PMID: 22570929.
- [pubmed] Zhang J, et al. "Caspofungin versus liposomal amphotericin B for treatment of invasive fungal infections or febrile neutropenia." Chin Med J (Engl), 2014;127(4):753-7. PMID: 24534235.
- [pubmed] Migoya EM, et al. "Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants." J Clin Pharmacol, 2011;51(2):202-11. PMID: 20679501.
- [pubmed] Mattiuzzi GN, et al. "Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies." Antimicrob Agents Chemother, 2006;50(1):143-7. PMID: 16377679.
Sources & Citations
Studies were read from their PubMed abstracts; the caspofungin label from DailyMed (Sagent, set 08fb61ee, effective July 29, 2026) through openFDA, read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.